Revista Polo del Conocimiento


Polo del Conocimiento

Hipoglucemia en pacientes diabéticos en tratamiento con glibenclamida

Jorge Morales, José Andrés Rodríguez Meza

Resumen


La glibenclamida consiste en un potente hipoglicemiante que permite mantener los niveles séricos de glucosa por debajo de los puntos de corte para el paciente diabético, cuyo empleo puede significar un riesgo mayor de hipoglicemia como complicación aguda en relación con otros hipoglicemiantes orales. La presente revisión narrativa presento como objeto la recopilación de información actualizada acerca del mecanismo de la hipoglicemia durante el tratamiento con glibenclamida, los factores de riesgo del paciente diabético y la frecuencia con la que puede sufrir hipoglicemia. La glibenclamida inhibe los canales de potasio dependientes de ATP en las células beta del páncreas, estimulando la secreción de insulina a este nivel. Su función es independiente de los niveles séricos de glucosa, y se ve potenciada en casos como pacientes con diabetes de varios años de evolución, pacientes longevos o insuficientes renales. Dosis elevadas o el empleo de otros medicamentos que potencien su acción también representan factores de riesgo. La frecuencia de la hipoglicemia en el paciente que utiliza glibenclamida a pesar de ser subestimada, se considera que puede presentarse en 1 de cada 5 pacientes. Las características de la glibenclamida hacen que este fármaco tenga a la hipoglicemia como su principal efecto adverso, afectando directamente al estilo de vida del paciente diabético, que se ha declinado por suspender el tratamiento o solicitar un cambio en su medicación.


Palabras clave


Glibenclamida; hipoglucemia; humano

Referencias


Aghaali, M., & Saghafi, H. (2018). Comparing the incidence of hypoglycemia episodes in patients with type 2 diabetes and chronic kidney disease treated with insulin or glibenclamide. Clinical Diabetology, 7(3), 129–135. https://doi.org/10.5603/DK.2018.0012

Andersen, S. E., & Christensen, M. (2016). Hypoglycaemia when adding sulphonylurea to metformin: a systematic review and network meta-analysis. British Journal of Clinical Pharmacology, 1291–1302. https://doi.org/10.1111/bcp.13059

Caballero-Corchuelo, J., Guerrero-Pérez, F., García-Sancho de la Jordana, P., & Pérez-Maraver, M. (2019). Analysis of the characteristics of patients with diabetes mellitus who attend a tertiary hospital emergency department for a hypoglycemic event. Endocrinología, Diabetes y Nutrición (English ed.), 66(1), 19–25. https://doi.org/10.1016/j.endien.2018.06.007

Casanova, L., Montero, M., Yarza, J., Legarreta, J., & Flores, M. (2017). Hipoglucemia grave en pacientes con diabetes mellitus 2 y azoados normales. Medicina Interna de Mexico, 33(6), 739–745. https://doi.org/10.24245/mim.v33i6.1422

Clemens, K. K., McArthur, E., Dixon, S. N., Fleet, J. L., Hramiak, I., & Garg, A. X. (2015). The Hypoglycemic Risk of Glyburide (Glibenclamide) Compared with Modified-Release Gliclazide. Canadian Journal of Diabetes, 39(4), 308–316. https://doi.org/10.1016/j.jcjd.2015.01.001

Confederat, L., Sandra, C., Hancianu, M., & Profire, L. (2020). Hypoglycemia induced by antidiabetic sulfonylureas. Revista medico-chirurgicala a Societatii de Medici si Naturalisti din Iasi, 119(2).

Elbahwy, I. A., Ibrahim, H. M., Ismael, H. R., & Kasem, A. A. (2017). Enhancing bioavailability and controlling the release of glibenclamide from optimized solid lipid nanoparticles. Journal of Drug Delivery Science and Technology, 38, 78–89. https://doi.org/10.1016/j.jddst.2017.02.001

Eriksson, J. W., Bodegard, J., Nathanson, D., Thuresson, M., Nyström, T., & Norhammar, A. (2016). Sulphonylurea compared to DPP-4 inhibitors in combination with metformin carries increased risk of severe hypoglycemia, cardiovascular events, and all-cause mortality. Diabetes Research and Clinical Practice, 117, 39–47. https://doi.org/10.1016/j.diabres.2016.04.055

Freeland, B. (2017). Hypoglycemia in Diabetes Mellitus. Home healthcare now, 35(8), 414–419.

Furman, B. (2017). Glibenclamide. En Reference Module in Biomedical Sciences (Número January, pp. 1–4). Elsevier Inc. https://doi.org/10.1016/B978-0-12-801238-3.97414-2

Goldstein, D., Chodick, G., Shalev, V., Thorsted, B. L., Elliott, L., & Karasik, A. (2016). Use of Healthcare Services Following Severe Hypoglycemia in Patients with Diabetes: Analysis of Real-World Data. Diabetes Therapy, 7(2), 295–308. https://doi.org/10.1007/s13300-016-0169-8

Gonzalez, C., Monti, C., Pinzon, A., Monsanto, H., & Ejzykowicz, F. (2018). Prevalence of hypoglycemia among a sample of sulfonylurea-treated patients with Type 2 diabetes mellitus in Argentina: The real-life effectiveness and care patterns of diabetes management (RECAP-DM) study. Endocrinologia, Diabetes y Nutricion, 65(10), 592–602. https://doi.org/10.1016/j.endinu.2018.05.014

Hussain, A., Ali, I., Khan, A. U., & Khan, T. M. (2016). Glibenclamide-induced profound hypoglycaemic crisis : a case report. Therapeutic Advances in Endocrinology and Metabolism, 7(2), 84–87. https://doi.org/10.1177/2042018816632440

Ikeda, T., Tani, N., Oritani, S., Shida, A., Aoki, Y., Morioka, F., & Ishikawa, T. (2018). Toxicological and Biochemical Analyses of an Autopsy Case Involving Oral Overdose of Multiple Antidiabetic and Antihypertensive Drugs. Case Reports in Medicine, 2018.

Ikeda, Y., Kubo, T., Oda, E., Abe, M., & Tokita, S. (2018). Incidence rate and patient characteristics of severe hypoglycemia in treated type 2 diabetes mellitus patients in Japan: Retrospective Diagnosis Procedure Combination database analysis. Journal of Diabetes Investigation, 9(4), 925–936. https://doi.org/10.1111/jdi.12778

Johnson-Rabbett, B., & Seaquist, E. R. (2019). Hypoglycemia in diabetes: The dark side of diabetes treatment. A patient-centered review. Journal of Diabetes, 11(9), 711–718. https://doi.org/10.1111/1753-0407.12933

Joy, N. G., Tate, D. B., & Davis, S. N. (2015). Counterregulatory Responses to Hypoglycemia Differ between Glimepiride and Glyburide in Non Diabetic Individuals Nino. Metabolism, 64(6), 729–737. https://doi.org/10.1016/j.metabol.2015.02.006.Counterregulatory

Kalra, S., Baruah, A. K. D. M. P., Arundhati, A. G. U., Parag, D., & Rakesh, S. (2019). Glucocrinology of Modern Sulfonylureas : Clinical Evidence and Practice-Based Opinion from an International Expert Group. Diabetes Therapy, 10(5), 1577–1593. https://doi.org/10.1007/s13300-019-0651-1

Klonoff, D. C., Alexander Fleming, G., Muchmore, D. B., & Frier, B. M. (2017). Hypoglycemia evaluation and reporting in diabetes: Importance for the development of new therapies. Diabetes/Metabolism Research and Reviews, 33(5). https://doi.org/10.1002/dmrr.2883

Leonard, C., Bilker, W., Brensinger, C., Han, X., Flory, J., Flockhart, D., Gagne, J., Cardillo, S., & Hennessy, S. (2016). Severe hypoglycemia in users of sulfonylurea. Clin Pharmacol Ther, 99(5), 538–547. https://doi.org/10.1002/cpt.297.SEVERE

Llinás, R., Alvis, L., & Mendoza, L. (2017). Evaluación de la prescripción de glibenclamida en diabéticos tipo 2. Rev Univ Ind Santander Salud, 49(1).

Matsuoka, A., Hirota, Y., Takeda, A., Kishi, M., Hashimoto, N., Ohara, T., Higo, S., Yamada, H., Nakamura, T., Hamaguchi, T., Takeuchi, T., Nakagawa, Y., Okada, Y., Sakaguchi, K., & Ogawa, W. (2020). Relationship between glycated hemoglobin level and duration of hypoglycemia in type 2 diabetes patients treated with sulfonylureas: A multicenter cross-sectional study. Journal of Diabetes Investigation, 11(2), 417–425. https://doi.org/10.1111/jdi.13132

Mohan, V., Cooper, M. E., Matthews, D. R., & Khunti, K. (2019). The Standard of Care in Type 2 Diabetes: Re-evaluating the Treatment Paradigm. Diabetes Therapy, 10(s1), 1–13. https://doi.org/10.1007/s13300-019-0573-y

Nachum, Z., Zafran, N., Salim, R., Hissin, N., Hasanein, J., Gam, Y., & Letova, Z. (2017). Glyburide Versus Metformin and Their Combination for the Treatment of Gestational Diabetes Mellitus : A Randomized Controlled Study. Diabetes Care, 1–6. https://doi.org/10.2337/dc16-2307

Nistor, M., Schmidt, M., Graul, I., Rakers, F., & Schiffner, R. (2019). A systematic review of neuroprotective strategies in the management of hypoglycemia. International Journal of Molecular Sciences, 20(3). https://doi.org/10.3390/ijms20030550

Ostovan, A., Ghaedi, M., Arabi, M., & Asfaram, A. (2017). Hollow porous molecularly imprinted polymer for highly selective clean-up followed by influential preconcentration of ultra-trace glibenclamide from bio-fluid. Journal of Chromatography A, 1520, 65–74. https://doi.org/10.1016/j.chroma.2017.09.026

Pardeep, K., Munish, K., Jyoti, P., & Prasad, D. N. (2019). Oral hypoglycemic drugs : An overview. Journal of Drug Delivery and Therapeutics Open, 9(3), 770–777.

Rashid, F., Abdelgadir, E., & Line, B. (2019). Diabetes & Metabolic Syndrome : Clinical Research & Reviews A systematic review on ef fi cacy and safety of the current hypoglycemic agents in patients with diabetes during Ramadan fasting. Diabetes & Metabolic Syndrome: Clinical Research & Reviews, 13(2), 1413–1429. https://doi.org/10.1016/j.dsx.2019.02.005

Samya, V., Shriraam, V., Jasmine, A., Akila, G. V., Anitha Rani, M., Durai, V., Gayathri, T., & Mahadevan, S. (2019). Prevalence of Hypoglycemia Among Patients With Type 2 Diabetes Mellitus in a Rural Health Center in South India. Journal of Primary Care and Community Health, 10. https://doi.org/10.1177/2150132719880638

Sarkar, B. K. , Akter, R. , Das, J. , Das, A. , Modak, P. , Halder, S., Sarkar, A. P. and Kundu, S. K. . (2019). Diabetes mellitus: A comprehensive review. Journal of Pharmacognosy and Phytochemistry, 8(3), 2362–2371. http://services.igi-global.com/resolvedoi/resolve.aspx?doi=10.4018/IJHISI.2016100104

Schloot, N., Haupt, A., Schütt, M., Badenhoop, K., Laimer, M., Nicolay, C., Reaney, M., Fink, K., & Holl, R. (2015). Risk of severe hypoglycemia in sulfonylurea-treatedpatients from diabetes centers in Germany/Austria:How big is the problem? Which patients are at risk? Diabetes/Metabolism Research and Reviews, 32, 316–324. https://doi.org/10.1002/dmrr

Sepúlveda, C., Palomo, I., & Fuentes, E. (2017). Antiplatelet activity of drugs used in hypertension, dyslipidemia and diabetes: Additional benefit in cardiovascular diseases prevention. Vascular Pharmacology, 91, 10–17. https://doi.org/10.1016/j.vph.2017.03.004

Sola, D., Rossi, L., Schianca, G. P. C., Maffioli, P., Bigliocca, M., Mella, R., Corlianò, F., Paolo Fra, G., Bartoli, E., & Derosa, G. (2015). Sulfonylureas and their use in clinical practice. Archives of Medical Science, 11(4), 840–848. https://doi.org/10.5114/aoms.2015.53304

Tan, X., Yang, L., Khunti, K., Zhang, R., Zhang, Y., Rajpathak, S., & Yu, M. (2021). Factors associated with switching from sulphonylureas to dipeptidyl peptidase 4 inhibitors among patients with type 2 diabetes in the United States. Diabetes, Obesity and Metabolism, 23(10), 2251–2260. https://doi.org/10.1111/dom.14466

Tourkmani, A. M., Alharbi, T. J., Rsheed, A. M. B., AlRasheed, A. N., AlBattal, S. M., Abdelhay, O., Hassali, M. A., Alrasheedy, A. A., Al Harbi, N. G., & Alqahtani, A. (2018). Hypoglycemia in Type 2 Diabetes Mellitus patients: A review article. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 12(5), 791–794. https://doi.org/10.1016/j.dsx.2018.04.004

Waitman, J., Caeiro, G., Romero, S., Ré, D., Daghero, A., Gonzalez, C., & Umpierrez, G. (2017). Endocrinología , Diabetes y Nutrición Social vulnerability and hypoglycemia among patients with diabetes. Endocrinología, Diabetes y Nutrición, 64(2), 92–99.

Wazaify, M., Abushams, L., & Claire, M. (2019). Abuse of sulfonylureas : Is factitious hypoglycemia a cause for concern ? International Journal of Clinical Pharmacy, 0123456789, 18–20. https://doi.org/10.1007/s11096-018-0767-9

Zhai, S., Georgy, A., Liang, Z., & Zhi, J. (2016). Pharmacokinetic and Pharmacodynamic Drug Interaction Study of Piragliatin, a Glucokinase Activator, and Glyburide, a Sulfonylurea, in Type 2 Diabetic Patients. Clinical Pharmacology in Drug Development, 5(6), 552–556. https://doi.org/10.1002/cpdd.276

Zhang, G., Lin, X., Zhang, S., Xiu, H., Pan, C., & Cui, W. (2017). Review Article A Protective Role of Glibenclamide in Inflammation- Associated Injury. Mediators of Inflammation, 2017. https://doi.org/10.1155/2017/3578702

Zhou, J., Kang, X., Luo, Y., Yuan, Y., Wu, Y., Wang, M., & Liu, D. (2019). Glibenclamide-Induced Autophagy Inhibits Its Insulin Secretion-Improving Function in β Cells. International Journal of Endocrinology, 2019. https://doi.org/10.1155/2019/1265175

Zhou, M., Wang, S. V, Leonard, C. E., Gagne, J. J., Fuller, C., Hampp, C., Archdeacon, P., Toh, S., Iyer, A., Siu, T., Cavagnaro, E., Panozzo, C. A., Axtman, S., Ryan, M., Chrischilles, E. A., & Hennessy, S. (2017). Sentinel Modular Program for Propensity-Score Matched Cohort Analyses: Application to Glyburide, Glipizide, and Serious Hypoglycemia. Epidemiology, 28(6), 838–846. https://doi.org/10.1097/EDE.0000000000000709.Sentinel

Zou, Y., Zhou, C., Xu, H., Yu, J., Ye, P., Zhang, H., Chen, S., Zhao, J., Le, S., Cui, J., Jiang, L., Wu, J., & Xia, J. (2020). Glibenclamide ameliorates transplant-induced arteriosclerosis and inhibits macrophage migration and MCP-1 expression. Life Sciences, 241, 117141. https://doi.org/10.1016/j.lfs.2019.117141


Texto completo: PDF HTML xml

DOI: 10.23857/pc.v7i6.4150

Enlaces de Referencia

  • Por el momento, no existen enlaces de referencia




Polo del Conocimiento              

Revista Científico-Académica Multidisciplinaria

ISSN: 2550-682X

Casa Editora del Polo                                                 

Manta - Ecuador       

Dirección: Ciudadela El Palmar, II Etapa,  Manta - Manabí - Ecuador.

Código Postal: 130801

Teléfonos: 056051775/0991871420

Email: [email protected][email protected]

URL: https://www.polodelconocimiento.com/

 

 

            



Top